Background. There is increased interest in locoregional recurrences of rectal cancer. Despite comparable locoregional recurrence rates in colon cancer, only a few studies on locoregional recurrences among colon cancer patients have been published. This study was designed to identify prognostic factors for locoregional recurrences among patients with colon cancer in the Netherlands. Methods. The study population was composed of patients who underwent radical surgical resections for invasive colon carcinoma, diagnosed in three regions of the Netherlands from 2000 to 2003. The Kaplan-Meier method was used to calculate 5-year locoregional recurrence rates (LRR). Conditional hazard rates were estimated by the lifetable method. Multivariate Cox regression analyses were performed to identify prognostic factors and to calculate a Locoregional Recurrence Risk Score (LRRS). Results. In total 127 of 2,282 patients developed locoregional recurrences within 5 years (LRR 6.4%). The risk of developing a locoregional recurrence was highest at 0.5-1 year after surgery. Patients with left-sided tumors, T3-T4 tumors, and positive lymph nodes and those who did not receive adjuvant chemotherapy were more likely to develop locoregional recurrences. Four risk groups based on the LRRS were defined. Five-year LRR was 2.5% for the very low-risk group and 25.1% for the high-risk group.
INTRODUCTION
Colon cancer is the third most common cancer in the Netherlands. The relatively high incidence is comparable to incidences in other western countries. In 2008, colon cancer was diagnosed in more than 8,100 new patients in the Netherlands, while 3,750 patients died of this in the same year, making this malignancy the second most frequent cause of cancer-related death. 1, 2 Survival among patients with colon cancer used to be higher compared with survival among patients with rectal cancer. 3 However, several changes in the treatment of rectal cancer have been introduced, including the introduction of the total mesorectal excision (TME) technique and a shift from postoperative to preoperative radiotherapy. 4, 5 Due to these changes, survival of all patients with rectal cancer increased more rapidly compared with that of patients with colon cancer. Currently, survival among patients with rectal cancer is higher compared with that among patients with colon cancer. 6 The changes in treatment also resulted in an increased interest in locoregional recurrences among patients with rectal cancer. In contrast, only a few studies on locoregional recurrences among patients with colon cancer have been published. Two studies comparing the locoregional recurrence rates of colon and rectal tumors revealed that the risk among patients with colon cancer was comparable to that among patients with rectal cancer, and reported rates of 10.2 and 6.0% for rectal cancer and 6.2 and 8.5% for colon cancer, respectively. 7, 8 The overall survival of colon cancer patients who develop locoregional recurrences after their initial treatment is generally poor. 9 Identification of factors that may influence the risk of locoregional recurrences is the next step in the process of prevention. Several factors have already been found to be associated with locoregional recurrence, i.e., emergency surgery, bowel perforation, surgeon's interest in colorectal surgery, poor differentiation of the tumor, and advanced stage. [9] [10] [11] [12] [13] Most of these studies, however, were performed in a hospital-based setting.
The purpose of this population-based study was to describe the incidence of locoregional recurrences in a large cohort of patients with colon cancer, to identify prognostic factors, and to define risk groups for locoregional recurrences based on the combination of the prognostic factors.
METHODS

Cancer Registry
All newly diagnosed cancer cases have been registered in the nationwide population-based Netherlands Cancer Registry (NCR) since 1989. Notification is obtained from the automated national pathological archive (PALGA) and from hematology and radiotherapy departments. The National Registry of Hospital Discharge Diagnoses also is an important source, accounting for up to 8% of new cases that were not obtained from PALGA.
14 Data are collected from patient files in the hospital by specially trained registration clerks. Topography and morphology are coded according to the International Classification of Diseases for Oncology (ICD-O), 15 and the TNM classification is used for staging of the tumors. 16 The dataset includes patient and tumor characteristics and information about treatment and follow-up. The vital status of all patients is complete up to Feb 2009 by linking deaths from the municipality registry to the cancer registry.
Patients
Data on recurrences were available for patients who underwent a radical surgical resection for invasive colon carcinoma unknown pathological stage and/or those who had a preceding invasive cancer were excluded from this study.
Information about local recurrences, regional recurrences, and distant metastasis is not collected routinely in the NCR. This was obtained by reviewing the medical records of all patients by the registration clerks of the NCR. Locoregional recurrence was defined as any histological or clinical evidence of tumor regrowth in or nearby the primary site after excision of the former tumor, irrespective of the presence or absence of distant metastases. Cases were generally followed for 5 years after surgery of the primary tumor. Detailed information about the follow-up program of all patients was not available, but most patients were followed at least once or twice per year. In accordance with the Dutch guidelines, follow-up for patients with colon tumors without distant metastases consists of regular clinical checks by a medical specialist, colonoscopy, CEA measurements, and ultrasounds of the liver. 17 For the analyses, pathological TNM stage was used. Site of the tumor was categorized into right-sided (C18.0-C18.3), transversum (C18.4), left-sided (C18.4-C18.7), and overlapping lesion of colon or not otherwise specified (C18.8-18.9).
Statistical Analyses
The Kaplan-Meier method was used to calculate 5-year locoregional recurrence rates. The life-table method was performed to estimate conditional hazard rates, defined as the probability of developing locoregional recurrence in a 6-month interval in the case that the patient is free of any recurrence, locoregional recurrence or distant metastases, or second primary colon tumor at the beginning of the interval. The conditional hazard rate at, for example, 1 year after surgery concerns the interval from 6 months to 1 year after surgery and is based on all patients who were free of recurrences at 6 months after surgery. To examine differences in patterns of recurrences, separate analyses were performed for patients with stage II and stage III disease. Due to the low number of locoregional recurrences in stage I, this stage was not analyzed separately but only included in the overall conditional hazard rates.
Prognostic factors for locoregional recurrences were analyzed using Cox regression, including gender, age at diagnosis, year of diagnosis, tumor site, depth of invasion, number of evaluated lymph nodes, number of positive lymph nodes, tumor grade, adjuvant chemotherapy, and CCC-region. Time to recurrence was calculated from the date of resection of the primary tumor to the date of diagnosis of the locoregional recurrence. Patients who did not have a locoregional recurrence were censored, and the time was calculated from date of resection to date of second primary colon tumor, date of death, or date of last follow-up. Separate analyses were conducted to examine differences in prognostic factors for developing a locoregional recurrence only (including diagnosis of a distant metastasis after the diagnosis of a locoregional recurrence) and for developing a locoregional recurrence combined with a distant metastasis diagnosed before or at time of diagnosis of the locoregional recurrence.
Furthermore, a risk score was calculated based on tumor factors. Risk points for each prognostic factor were defined by multiplying the regression coefficients (b) from the multivariate model with 10 and rounding it to a whole number. For each individual patient, a Locoregional Recurrence Risk Score (LRRS) was calculated by summing the risk points of each prognostic factor. Based on the LRRS, four risk groups were defined using receiver operating characteristics (ROC) analysis. For all analyses, STATA version 10.0 was used. A P value \0.05 was considered to be statistical significant.
RESULTS
In total, 2,282 patients with colon cancer were included in this study. Table 1 shows the characteristics of the study population. Overall, 48% were male and 38% were aged 75 years or older at the time of diagnosis. Almost half of the tumors were stage IIA (T3N0M0). Twenty-three percent of all patients had one to three positive lymph nodes. The proportion of patients in the total study population who received adjuvant chemotherapy was 25%. Sixteen percent of the patients with stage IIB disease and 59% of the patients with stage III disease received adjuvant chemotherapy. Median follow-up time was 5.0 years. Locoregional recurrences were diagnosed in 127 patients within 5 years after surgery of the primary tumor, of which 39 patients (31%) underwent surgical treatment. Almost all patients (97%) who did not undergo surgical treatment died, with a median time between locoregional recurrence and death of 0.4 years ( Fig. 1) .
Of all patients with a locoregional recurrence, 57 patients only had a locoregional recurrence and 30 patients were diagnosed with a distant metastasis after the diagnosis of the locoregional recurrence. In this group, the median time between locoregional recurrence and detection of distant metastasis was 108.5 days. Forty patients had a locoregional recurrence combined with a distant metastasis diagnosed before (n = 11) or at time (n = 29) of the diagnosis of the locoregional recurrence with a median time between distant metastasis and locoregional recurrence of 30 days.
Conditional Hazard Rate
Locoregional recurrences occurred at a median of 1.5 years after surgery of the primary tumor. Sixty-four percent of all recurrences were diagnosed within 2 years after surgery and 90% within 4 years. Figure 2 shows the conditional hazard rates for any locoregional recurrences (with or without distant metastasis) for each 6-month interval for the total study population and for stage II and III separately. There is one peak at the interval of 0.5-1 year after surgery with the highest conditional hazard rate of 0.0269, meaning that the probability of developing a locoregional recurrence in this interval was 2.7%. The same pattern was observed for stage II and III, with the highest conditional hazard rate at the interval of 0.5-1 year after surgery of respectively 0.0153 (1.5) and 0.0587 (5.9%).
Prognostic Factors
Overall, the 5-year LRR was 6.39% (95% confidence interval (CI), 5.39-7.56). A significant association was found between the 5-year LRR and pathological stage, depth of invasion, number of positive lymph nodes, and adjuvant chemotherapy. Figure 3 shows the locoregional recurrence rate according to stage. There was no significant association between number of evaluated lymph nodes and LRR. Furthermore, no significant relationship was found between LRR and CCC-regions ( Table 1 ). The 5-year LRR differed between hospitals, ranging from 0 to 28%, but this association was not significant.
In the multivariate analysis, calculating prognostic factors for the risk of locoregional recurrences irrespective of distant metastases (Table 2) , patients with left-sided tumors were more likely to develop locoregional recurrences compared to patients with right-sided tumors (hazards ratio (HR), 1.61; 95% CI, 1.11-2.35). The risk of developing locoregional recurrences increased with increasing T-stage, up to a hazard ratio of 8.15 (95% CI, 1.85-35.87) for patients with pT4 tumors. Patients with positive lymph nodes had a higher risk of developing locoregional recurrences compared with patients without positive lymph nodes; patients with one to three positive lymph nodes had a hazard ratio of 2.92 (95% CI, 1.85-4.61), and patients with more than six positive lymph nodes had a hazard ratio of 5.29 (95% CI, 2.12-13.16). Overall, patients who did not receive adjuvant chemotherapy had a higher risk of developing locoregional recurrences (HR, 1.61; 95% CI, 1.04-2.49).
The same prognostic factors were revealed for the risk of locoregional recurrence only at time of diagnosis of the locoregional recurrence (including diagnosis of a distant metastasis after the locoregional recurrence). Only positive lymph nodes were a prognostic factor for the risk of developing a locoregional recurrence combined with a distant metastasis before or at the same time of the locoregional recurrence. In the subset of patients with pN? tumors, the risk of developing locoregional recurrences was higher among patients with four to six positive lymph nodes compared with those with one to three positive lymph nodes (HR, 2.16; 95% CI, 1.28-3.65; Table 3 ). No statistical difference in the risk of developing locoregional recurrences was found among patients with pN? tumors and among patients with pN0 tumors who received adjuvant chemotherapy compared with patients who did not receive adjuvant chemotherapy.
Risk Groups
The LRRS for each patient was calculated by adding all risk points of all prognostic tumor factors (LRRS = risk points (tumor site) ? risk points (depth of invasion) ? risk points (number of positive lymph nodes); Table 2 ). Based on the LRRS, the total population was split into four risk groups: very low, low, intermediate, and high risk. Very low risk was defined as a LRRS score of 0-14 points, low risk as a LRRS score of 15-18 points, intermediate risk as a LRRS score of 19-25 points, and high risk as a LRRS score of [25 points. The 5-year LRR was 2.3% for the very lowrisk group, 5.1% for the low-risk group, 9.3% for the intermediate risk group, and 14.7% for the high-risk group (Fig. 4) .
DISCUSSION
The results of this population-based study, analyzing the data of 2,282 patients with colon cancer, demonstrated a 5-year locoregional recurrence rate of 6.4%. The risk of Compared with other studies, the locoregional recurrence rate was relatively low in our study. We calculated a locoregional recurrence rate of 6.4% after 5 years of follow-up, whereas others described rates of 11.5 and 12.8%. 9, 12 The variations between regions (5-year LRR range, 6-8.2%) and between hospitals (5-year LRR range, 0-28%) were not significant.
One of the prognostic factors was tumor site. Tumors in the transversum had the highest 5-year locoregional recurrence rate. However, the number of patients with a tumor in the transversum was low and in the multivariate analyses only left-sided tumors had a significant higher risk of locoregional recurrence compared with right-sided tumors. One possible explanation is the tendency of leftsided tumors to have more segmental resections without clearance of the central lymph nodes close to the base of the inferior mesenteric artery. Another explanation could be that this is a result of the biological differences between left-sided and right-sided tumors. 18 An American singleinstitution study did not find an association between tumor site and risk of local recurrence.
11 Similar to other studies, 9, 11, 12 we found an increased risk of locoregional recurrences in more advanced tumors, i.e., a larger depth of invasion and (more) positive lymph nodes.
In rectal cancer care, the introduction of total mesorectal excision resulted in a decreased local recurrence rate. 19 In the Netherlands, this technique was introduced within the framework of the Dutch TME trial, in which the Dutch Colorectal Cancer Group investigated the effects of preoperative radiotherapy in combination with standardized TME. 20 The technique of TME was translated into colon cancer surgery. Complete mesocolic excision (CME) is still not considered standard surgery in the Netherlands. However, results from a German study demonstrated lower local recurrence rates and better overall survival using CME. 21 A review suggested that the relation between higher lymph node yield and better survival reflects the quality of the surgical resection. 22 An explanation could be that surgeons have performed a more complete resection with a more extensive lymph node resection, which may subsequently lead to a lower risk of locoregional recurrence. However, our study demonstrated no association between number of evaluated lymph nodes and risk of locoregional recurrence.
Several randomized trials demonstrated the benefit of adjuvant chemotherapy in stage III disease. 23, 24 In the total study population, patients who received adjuvant chemotherapy had a lower risk of locoregional recurrence. In a subgroup analysis, among node-negative and node-positive patients the risk of locoregional recurrence was lower among patients who received adjuvant chemotherapy compared with patients who did not. However, statistical significance was not reached in this subgroup analysis. According to the Dutch guidelines, adjuvant chemotherapy should be considered for patients with high-risk stage II disease, e.g., T4 tumors. 17 With regard to depth of Knowledge about patterns of recurrences is important for the follow-up schedule of colon cancer patients. In this study, the median time between surgery of the primary tumor and diagnosis of the locoregional recurrence was 1.5 years and the highest risk of locoregional recurrence was found in the period from 6 months to 1 year after surgery of the primary tumor, suggesting that follow-up during approximately the first 2 years is the most essential period for detecting locoregional recurrences assuming that early detection is important. However, the intensity of follow-up programs after colorectal cancer is still unclear. A Cochrane review revealed an overall survival benefit for a more intensive follow-up program compared with a less intensive followup, but the best combination and frequency of visits and diagnostic tests remained unclear due to the large variation in the follow-up programs. 25 However, in only one of the eight studies included in this review, patients were randomly allocated to a specific follow-up program based on their risk of developing a recurrence. The validity of our LRRS would be worthwhile to test to form the base for further studies with different follow-up schedules.
In the present study, the number of evaluated lymph nodes was very low. The Dutch guidelines recommend a minimum of ten evaluated lymph nodes, meaning that almost 60% of the lymph node evaluations were inadequate. Patients with a low number of evaluated lymph nodes could be wrongly categorized as node-negative, which could lead to undertreatment of these patients. This may affect our results, especially the analyses by nodal involvement.
In conclusion, although the locoregional recurrence rate in this study was relatively low, it remains a considerable problem. Patients with left-sided tumors, with a larger depth of invasion and positive lymph nodes, and those who did not receive adjuvant chemotherapy were more likely to develop a locoregional recurrence. Identifying individual patients who might benefit from adjuvant chemotherapy may reduce the locoregional recurrence rate.
